Migraine Drugs Market: By Drug Type,, Abortive ), By Route of Administration, By Distribution Channel, Region Forecast 2020-2031
Migraine Drugs Market size was valued at US$ 6.0 billion in 2024 and is expected to reach US$ 11.4 billion by 2031, growing at a significant CAGR of 9.50% from 2025-2031. Migraine Drugs Market is a primary headache disorder characterized by moderate to a severe headache. Typically migraine headaches affect half of the head and are generally pulsatile. A migraine may last in the range of two hours to 72 hours. Other symptoms may include nausea, vomiting, and sensitivity to light, smell, and sound. Migraines may be preceded by an aura of sensory disturbances followed by severing an often onside headache.
There are two types of migraine drugs are present in the market. Prophylactic drugs are used for the prevention of precedence of migraine. Whereas, no particular migraine therapy drugs are available. The market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, the rise in R&D activities by the market players to develop new drugs and the expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in the population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share.
However, availability of the generic drugs and other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period. The global migraine drugs market is expected to grow at a significant rate owing to the prevalence of migraine worldwide. The market is witnessing acquisitions and mergers of the market players.
Study Period
2025-2031Base Year
2024CAGR
9.4%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Global migraine drugs market is mainly driven by the increase in the prevalence of migraine worldwide. In addition, rise in R&D activities by the market players to develop new drugs and expected commercialization of the pipeline drugs are projected to bolster the market during the forecast period. Furthermore, growing awareness in population regarding early diagnosis and treatment of migraine coupled with the rise in healthcare expenditure globally projected to boost the global market share. However, availability of the generic drugs, other treatment options such as neuromodulators and others expected to impede the market global migraine drugs market over the forecast period.
Geographically migraine drugs market is divided into five key regions, i.e. Europe, North America, Latin America, Asia- Pacific, and The Middle East & Africa. North America market is anticipated to grow at significant rates owing to the factors such as rise in the occurrence of migraine, greater healthcare expenditure, and recent product launches. Asia Pacific market is expected to have notable market growth over the forecast period owing to the growth in a number of people suffering from the migraine and growing awareness related to early diagnosis and treatment. China and India expected to have lucrative growth opportunities owing to the lifestyle changes and high prevalence rates of migraine in the countries
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 6.0 billion |
|
Market Size in 2031 |
US$ 11.4 billion |
|
Market CAGR |
9.4% |
|
By Drug Type |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The migraine drugs market size was valued at US$ 6.0 billion in 2024 and is expected to reach US$ 11.4 billion by 2031, growing at a significant CAGR of 9.50% from 2025-2031.
The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The market key players AstraZeneca Plc. (U.K.), Allergan Plc. (U.S.), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline plc (U.K), Eli Lilly & Co. (U.S.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Valeant Pharmaceutical International, Inc. (Canada), Janssen Pharmaceutical Company (Johnson & Johnson) (U.S.), Endo International plc. (U.S.), Zosano Pharma Inc. (U.S.), Alder Biopharmaceuticals (U.S.)
| 1. Executive Summary |
| 2. Global Migraine Drugs Market Introduction |
| 2.1.Global Migraine Drugs Market - Taxonomy |
| 2.2.Global Migraine Drugs Market - Definitions |
| 2.2.1.Drug Type |
| 2.2.2.Route of Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Migraine Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Migraine Drugs Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Migraine Drugs Market By Drug Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Prophylactic |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Abortive |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Migraine Drugs Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Injectables |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Oral |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Migraine Drugs Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Migraine Drugs Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Migraine Drugs Market, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Prophylactic |
| 9.1.2.Abortive |
| 9.2. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Injectables |
| 9.2.2.Oral |
| 9.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Others |
| 9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10. Europe Migraine Drugs Market, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Prophylactic |
| 10.1.2.Abortive |
| 10.2. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Injectables |
| 10.2.2.Oral |
| 10.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Others |
| 10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11. Asia Pacific (APAC) Migraine Drugs Market, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Prophylactic |
| 11.1.2.Abortive |
| 11.2. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Injectables |
| 11.2.2.Oral |
| 11.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Others |
| 11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12. Middle East and Africa (MEA) Migraine Drugs Market, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Prophylactic |
| 12.1.2.Abortive |
| 12.2. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Injectables |
| 12.2.2.Oral |
| 12.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Others |
| 12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Migraine Drugs Market, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Prophylactic |
| 13.1.2.Abortive |
| 13.2. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Injectables |
| 13.2.2.Oral |
| 13.3. Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Others |
| 13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AstraZeneca Plc. (U.K) |
| 14.2.2.Allergan Plc. (U.S) |
| 14.2.3.Pfizer, Inc. (U.S) |
| 14.2.4.Teva Pharmaceutical Industries Ltd. (Israel) |
| 14.2.5.GlaxoSmithKline plc (U.K) |
| 14.2.6.Eli Lilly & Co. (U.S) |
| 14.2.7.Novartis AG (Switzerland) |
| 14.2.8.Merck & Co., Inc. (U.S) |
| 14.2.9.Valeant Pharmaceutical International, Inc. (Canada) |
| 14.2.10.Janssen Pharmaceutical Company (Johnson & Johnson) (U.S) |
| 14.2.11.Endo International plc. (U.S) |
| 14.2.12.Zosano Pharma Inc. (U.S) |
| 14.2.13.Alder Biopharmaceuticals (U.S) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
